SGS Life Science Services Opens Center of Excellence for Biophysical Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SGS Life Science Services Opens Center of Excellence for Biophysical Analysis


SGS Life Science Services has completed the development of a Center for Excellence for biophysical analysis of biopharmaceutical products in its SGS M-Scan facility in Wokingham, the United Kingdom.

The biophysical analysis group is lead by Dr.Iñigo Rodriguez-Mendieta, who along with his team, provides expertise in higher order structure analysis. The team can perform aggregation analysis, secondary/tertiary structural analysis, and thermal stability assessment and comparison. The new center complements the company's recent investment, announced in March 2013, to develop integrated formulation and stability testing services at the Wokingham facility, slated for completion in the fourth quarter 2013 and to be fully validated by early 2014.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here